Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement? (Record no. 25870546)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01173 a2200277 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517085830.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201608s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2047-9980 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1161/JAHA.116.003440 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Luzum, Jasmine A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20160824 |
| 245 00 - TITLE STATEMENT | |
| Title | Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement? |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of the American Heart Association |
| Date of publication, distribution, etc. | Mar 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | e003440 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Angiotensin-Converting Enzyme Inhibitors |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Coronary Artery Disease |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cost-Benefit Analysis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Perindopril |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmacogenetics |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lanfear, David E |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of the American Heart Association |
| Related parts | vol. 5 |
| -- | no. 3 |
| -- | p. e003440 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1161/JAHA.116.003440">https://doi.org/10.1161/JAHA.116.003440</a> |
| Public note | Available from publisher's website |
No items available.